Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza ...

Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...

Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration ...

Investing.com -- Novavax (NASDAQ: NVAX) stock rose 5% after the company announced positive preclinical results for its H5N1 avian influenza vaccine candidate, showing strong immune responses in ...

Novavax's H5N1 avian pandemic influenza vaccine candidate demonstrates immunogenicity in preclinical study: Gaithersburg, Maryland Friday, July 25, 2025, 15:00 Hrs [IST] Novavax, ...

Novavax, Inc. (NVAX) on Thursday announced preclinical data demonstrating that the company’s H5N1 bird flu vaccine candidate ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Novavax (NVAX) reached $7.64 at the closing of the latest trading day, reflecting a -2.55% change compared to its last close.

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

As the country continues to deal with the fallout of the infamous Jeffery Epstein files, The Root is taking a closer look at ...

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including Sanofi's $1.6B acquisition ...